InspireMD Appoints Recognized Interventional Cardiologist
TEL AVIV, Israel, April 29, 2021 (GLOBE NEWSWIRE) – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard ™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease , today announces the formation of its Scientific Advisory Board with its new chair, renowned interventional cardiologist, Kenneth Rosenfield, MD
The company intends for the Scientific Advisory Board to provide advice and direction on clinical needs, technological advancements and planning for the growth and strategic direction of the company.
Kenneth Rosenfield, MD, is the Section Head of Vascular Medicine and Intervention and chairs the Acute Myocardial Infarction (STEMI) Committee for the Cardiac Catheterization Laboratory at Massachusetts General Hospital. Dr. Rosenfield specializes in complex cardiac and vascular procedures. He is a past president and master of SCAI, past governor of the ACC for Massachusetts, recipient of the AHA Laennec Master Clinician Award and the Distinguished Mason Sones Award. Dr. Rosenfield has led the development of less invasive therapies for patients with coronary heart disease and vascular disease, both at the MGH and nationally, including the treatment of narrowing of the carotid arteries, renal and leg. using stents and other innovative devices. He has designed and served as the National Principal Investigator or Co-Principal for numerous landmark clinical trials including the Asymptomatic Carotid Artery Trial (ACT 1), the SUPERB SFA Stent Graft Trial, Balloon Trials drug coatings LEVANT 2 and TRANSCEND and the NIH BEST CLI test. A pioneer in carotid stent placement, Dr. Rosenfield placed the first carotid stents in New England and has been deeply involved in virtually every major carotid stent research initiative. He further led the effort to define qualifications, training, and standards for the carotid stent, and initiated the effort to create a carotid registry that was ultimately incorporated into the NIH CREST 2 trial as a registry. CREST 2.
“InspireMD’s DNA is based on research and development and the advancement of new technologies – such as our MicroNet® mesh used with our CGuard® EPS device – in the market. As our portfolio evolves and expands, we recognize the value that the esteemed physicians of this newly formed Scientific Advisory Board bring in validating and directing our efforts towards the highest levels of clinical utility, acceptance of physicians and patient outcomes, ”commented InspireMD CEO Marvin Slosman. “Dr. Rosenfield was a pioneer in cardiovascular medicine and a true supporter of CGuard EPS. We are delighted to have his support as we develop and bring new products to market, while strengthening CGuard EPS’s global reach in the US and Asian markets. We welcome him as Chairman of our Scientific Advisory Board and look forward to appointing members and establishing this important strategic board to guide our success.
“I firmly believe that CGuard EPS will set a new standard of care in the treatment of carotid artery disease, based on a comprehensive body of clinical evidence and its unique and proprietary design. The opportunity to improve patient outcomes with the carotid stent is exciting, and with the momentum of the upcoming C-Guardian trial and focus on the United States and other global markets, the future of the carotid stent is very promising. It is a privilege to work with management and industry thought leaders to provide input, direction and support to InspireMD’s plans. Added Dr Rosenfield.
About CGuard® EPS
The CGuard® Embolic Protection System is an advanced platform solution designed to offer the flexibility of the traditional open cell stent with advanced protection against peri-procedural and post-procedural embolic events caused by plaque prolapse through the strut of the stent that can lead to a stroke. CGuard’s unique MicroNet® technology mitigates prolapse and associated embolization and has shown superior clinical outcomes for patients compared to alternative carotid stent types, conventional and next-generation double-layered stents, and procedures invasive procedures such as endarterectomy, major surgery. InspireMD’s CGuard ™ has created a new dimension in the protected treatment of carotid artery disease and has the potential to set a new standard of care for the management of carotid artery disease and the prevention of accidents. cerebrovascular.
About InspireMD, Inc.
InspireMD seeks to use its patented MicroNet® technology to make its products the industry standard for carotid stenting by providing exceptional acute results and long-lasting, stroke-free, long-term results. For more information visit www.inspiremd.com. InspireMD regularly posts information that may be important to investors in the Investors section of its website.
This press release contains “forward-looking statements”. These statements may be preceded by the words “intends”, “may”, “will”, “plans”, “expects”, “anticipates”, “plans”, “predicts”, “estimates”, “aims”, “Believes”, “hopes”, “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company, and cannot be predicted or quantified and, by therefore, actual results may differ. materially in relation to those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or long product delays. in key markets, (iii) an inability to obtain regulatory approvals for the sale of our products, (iv) the impact of the COVID-19 pandemic on our manufacturing, sales, business plan and economy global, (v) intense competition in the medical device industry from much larger multinational companies, (vi) product liability claims, (vii) product malfunctions, (viii) our capabilities manufacturing and our reliance on subcontractors for support, (ix) insufficient or inadequate reimbursement by government and other third party payers for our products, (x) our efforts to successfully obtain and maintain the pr otection of intellectual property covering our products, which may not be successful, (xi) legislative or regulatory reform of the healthcare system in the United States and f or foreign jurisdictions, (xii) our reliance on single suppliers for certain components of products, (xiii) the fact that we will need to raise additional capital to meet our business needs in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiv) the fact that we operate in multiple foreign jurisdictions, which exposes us to fluctuations in foreign currency exchange rates, logistics and communications challenges, burdens and costs of compliance with foreign laws, and political and economic instability in each jurisdiction . More detailed information about the company and the risk factors that may affect the performance of forward-looking statements are set out in the company’s filings with the Securities and Exchange Commission (SEC), including the company’s annual report on Form 10-K and its quarterly. Reports on Form 10-Q. Investors and security holders are encouraged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.